TORONTO, CANADA — (February 21, 2020) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF), a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to announce that it has been named a TSX Venture 50™ company for the second consecutive year, in recognition of its performance on the TSX Venture Exchange.

The 2020 TSX Venture 50™ ranks the top ten performers on the TSX Venture Exchange in each of five industry sectors: Clean Technology and Life Sciences, Diversified Industries, Energy, Mining, and Technology. Winners were selected based on market capitalization growth, share price appreciation and trading volume for the 2019 calendar year.

“It’s exciting to be recognized as a TSX Venture top performer for the second year in a row. We believe this award reflects a growing awareness of the best-in-class potential of our drug pipeline,” commented Dan Legault, Antibe’s CEO. “We hope to continue this success for our shareholders, as we complete our lead drug’s final Phase 2 trial, expand partnering activities and evolve into a Phase 3 company. We look forward to reaching a growing audience of institutional and retail investors in the coming year.”

For more information on the TSX Venture 50™, including the ranking and list of this year’s winners, please visit:

About Antibe Therapeutics Inc.
Antibe develops safer, non-addictive medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce an improved medicine. Antibe’s lead drug, ATB-346, targets the global need for a safer, non-addictive drug for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent global need for a non-addictive analgesic for treating post-surgical pain, while ATB-340 is a GI-safe derivative of aspirin. Citagenix Inc., an Antibe subsidiary, is a market leader and worldwide distributor of regenerative medicine products for the dental marketplace.

Forward Looking Information
This news release includes certain forward-looking statements, which may include, but are not limited to, the completion of financing transactions and the licensing and development of drugs and medical devices. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “will”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “intend”, “propose” and similar expressions. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or implied in this news release. Factors that could cause actual results to differ materially from those anticipated in this news release include, but are not limited to, the Company’s ability to secure additional financing, its ability to execute its business strategy and successfully compete in the market, and risks associated with drug and medical device development generally. Antibe Therapeutics Inc. assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.

Contact Information
Antibe Therapeutics Inc.
Christina Cameron
VP Investor Relations
+1 416-922-3460

Read all news


This is an external link. Click “OK” to continue.